Stem Cell γδ T-Cell Differentiation With VCAM-ICAM-DLL4 Coating
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for obtaining γδ T cells are inefficient, resulting in a small initial number and requiring costly in vitro expansion, limiting the therapeutic efficacy of cellular immunotherapy.
Innovation Solution
A method involving the formation of a coating containing vascular cell adhesion molecule (VCAM), intercellular adhesion molecule (ICAM), and delta-like ligand 4 (DLL4) on a surface, combined with a cytokine combination of stem cell factor (SCF), thrombopoietin (TPO), Fms-like tyrosine kinase 3 ligand (Flt3L), and interleukin-7 (IL-7) to differentiate stem cells, particularly CD34 positive hematopoietic stem cells from umbilical cord blood or induced pluripotent stem cells into γδ T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If peripheral blood separation method is used to obtain γδ T cells, then the initial number of γδ T cells obtained is small, but the process is simple
Solution Approach 1:
The patent applies preliminary action by pre-coating the culture surface with VCAM, ICAM, and DLL4 molecules before introducing stem cells. This pre-prepared microenvironment enables direct differentiation into γδ T cells without requiring subsequent complex expansion procedures, thereby increasing the initial number of therapeutic cells while maintaining process simplicity
Solution Approach 2:
The patent changes the cultural parameters by introducing a specific combination of cytokines (SCF, TPO, Flt3L, IL-7) and adhesion molecules (VCAM, ICAM, DLL4) to create optimal conditions for γδ T cell differentiation. This parameter optimization enables efficient differentiation and expansion, solving the contradiction between obtaining sufficient cell numbers and maintaining process simplicity
2Quantity of substance
If in vitro expansion method is used to obtain sufficient therapeutic dose, then the therapeutic dosage can be increased, but the cost and time increase
Solution Approach 1:
By pre-establishing the appropriate microenvironment with adhesion molecules and cytokines, the patent enables stem cells to directly differentiate into γδ T cells at high efficiency from the beginning of culture. This preliminary setup eliminates the need for time-consuming sequential expansion steps, reducing both culture time and operational complexity while achieving sufficient therapeutic dosages
3Reliability
If autologous immune cells are used for cellular immunotherapy, then the treatment can be personalized, but the treatment results are unsatisfactory due to poor functioning of patient's immune cells
Solution Approach 1:
The patent creates allogeneic γδ T cells that can serve as universal donor cells, copying the therapeutic function needed by different patients. These standardized high-quality cells can be used across multiple patients, maintaining therapeutic efficacy while reducing the need for complex personalized cell preparation, thus solving the contradiction between reliability and adaptability
Data Source
AI summary
A method for preparing an immune cell differentiated from a stem cell is provided. The method includes: (a) forming a coating containing a matrix on a surface; and (b) culturing a stem cell on the coating in the presence of a first cytokine combination to differentiate the stem cell into an immune cell, wherein the immune cell includes a γδ T cell (gamma delta T cell, GDT cell). The matrix includes: vascular cell adhesion molecule (VCAM); intercellular adhesion molecule (ICAM); and delta-like ligand 4 (DLL4). The first cytokine combination includes: stem cell factor (SCF); thrombopoietin (TPO); Fms-like tyrosine kinase 3 ligand (Flt3L); and interleukin-7 (IL-7). Moreover, a source of the stem cell includes umbilical cord blood or an induced pluripotent stem cell (iPSC), and the stem cell is CD34 positive.